Curso
PHCY310 (S1 2019)
p3 2019
Módulos (32)
-
L3 Autonomic Nervous System
Explain the different components of the nervous system. Name the components that generate the sympathetic and parasympathetic responses of the autonomic nervous system. Describe the signaling molecules and receptor proteins involved in communication within the two divisions of the autonomic nervous system.
| Recurso do curso | Recurso original | Criado por |
|---|---|---|
| L3 Autonomic Nervous System | L3 Autonomic Nervous System | Mer Scott |
| L4 Sympathetic nervous system and adrenergic neurotransmission | L4 Sympathetic nervous system and adrenergic neurotransmission | Mer Scott |
| L6 The parasympathetic nervous system and cholinergic neurotransmission | L6 The parasympathetic nervous system and cholinergic neurotransmission | Mer Scott |
| L13 Asthma | L13 Asthma | Mer Scott |
| L14 Medicinal Chemistry | L14 Medicinal Chemistry | Mer Scott |
| L15 Clinical Pharmacology of Asthma | L15 Clinical Pharmacology of Asthma | Mer Scott |
| L16 Therapeutics of Asthma | L16 Therapeutics of Asthma | Mer Scott |
| L17 Lab Tests (Asthma) | L17 Lab Tests (Asthma) | Mer Scott |
| L18 Acute Respiratory Tract Infections | L18 Acute Respiratory Tract Infections | Mer Scott |
| L19 Rheumatic Fever | L19 Rheumatic Fever | Mer Scott |
| L20 Upper respiratory tract infections | L20 Upper respiratory tract infections | Mer Scott |
| L21 Ethics | L21 Ethics | Mer Scott |
| L22 Seasonal respiratory allergies | L22 Seasonal respiratory allergies | Mer Scott |
| L23 Risk factors for CVR disorders | L23 Risk factors for CVR disorders | Mer Scott |
| L24 Cardiovascular lab tests | L24 Cardiovascular lab tests | Mer Scott |
| L25 Medicinal Chemisty of Antihypertensives | L25 Medicinal Chemisty of Antihypertensives | Mer Scott |
| L26 Clinical pharmacology of hypertension | L26 Clinical pharmacology of hypertension | Mer Scott |
| L27 Therapeutics of Hypertension | L27 Therapeutics of Hypertension | Mer Scott |
| L28 Background hyperlipidemia | L28 Background hyperlipidemia | Mer Scott |
| L30 Therapeutics of hyperlipidemia | L30 Therapeutics of hyperlipidemia | Mer Scott |
| L31 Type 2 DM | L31 Type 2 DM | Mer Scott |
| L32 Clinical Pharmacolgy of T2DM | L32 Clinical Pharmacology of T2DM | Mer Scott |
| L33 Therapeutics of T2DM | L33 Therapeutics of T2DM | Mer Scott |
| L34 Community based support programmes for the management of diabetes | L34 Community based support programmes for the management of diabetes | Mer Scott |
| L34.5 CKD and AKI | L34.5 CKD and AKI | Mer Scott |
| L35,36,37 CKD Pharmacology, Therapeutics, Labs | L35,36,37 CKD Pharmacology, Therapeutics, Labs | Mer Scott |
| L38 Background T1DM | L38 Background T1DM | Mer Scott |
| L39 Insulins for optimal therapy | L39 Insulins for optimal therapy | Mer Scott |
| L41,42 Background/Pathology IHD | L41,42 Background/Pathology IHD | Mer Scott |
| L43 Therapeutics of IHD | L43 Therapeutics of IHD | Mer Scott |
| L44,45,46 Dysrhythmias | L44,45,46 Dysrhythmias | Mer Scott |
| L47 Anticoagulation | L47 Anticoagulation | Mer Scott |